Denosumab treatment in postmenopausal women with osteoporosis

Lancet Diabetes Endocrinol. 2017 Oct;5(10):767-768. doi: 10.1016/S2213-8587(17)30287-5.

Authors

Paul de Boissieu¹, Thierry Trenque²

Affiliations

¹ Epidemiology and Public Health Department, Kremlin-Bicêtre University Hospital, 94270 Le Kremlin-Bicêtre, France. Electronic address: paul.de-boissieu@u-psud.fr.
² Regional Center for Pharmacovigilance and Pharmacoepidemiology, Reims University Hospital, Reims, France.

PMID: 28938991
DOI: 10.1016/S2213-8587(17)30287-5

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal
Bone Density
Bone Density Conservation Agents
Denosumab*
Female
Humans
Osteoporosis
Osteoporosis, Postmenopausal
Postmenopause*

Substances

Antibodies, Monoclonal
Bone Density Conservation Agents
Denosumab